Patients don’t take their medicines because they don’t want to Debra is late getting up for work again. In her heart of ...

Global biotechnology leader CSL has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for ...

Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone has met the primary endpoint in the NEXUS trial ...

Bayer’s initiative reflects a broader effort to address the high unmet medical need in oncology. The trial’s success could ...

CatalYm has announced promising new data on its lead drug candidate, visugromab, at the 17th International Conference on ...

Immunocore has announced that Kimmtrak (tebentafusp) has been recommended for funding in England by the National Institute ...

Neuraxpharm Group has announced that the National Institute for Health and Care Excellence (NICE) has recommended ublituximab ...

New cell therapy shows potential in treating advanced blood disorder Cellenkos has unveiled new phase 1b data for its ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...

iOnctura has announced promising results from the phase 1 DIONE-01 study, showcasing the clinical activity and long-term ...

Everest Medicines has announced promising results from the Phase 1b/2a clinical trial of EVER001, a novel Bruton’s tyrosine ...

Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone met the primary endpoint in the NEXUS trial for ...